Archive: Company News
Company News: Curetis – Study Data Presented at ECCMID 2019 Confirm Clinical Benefits of Unyvero Platform
— Growing body of evidence shows benefits of Unyvero for antibiotic stewardship
— 8 new reports on European studies presented by clinical researchers using Unyvero HPN, ITI, BCU and IAI
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that novel products, data, and services will be presented during this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, The Netherlands, from April 13 – 16, 2019. Curetis can be found at booth 1.65 during the conference. Read more…
Company News: Curetis Introduces Unyvero AMR Atlas to Support Adoption of Rapid DNA Testing for Antibiotic Resistance
— Knowledge base of antimicrobial resistance (AMR) markers tailored specifically to Unyvero Applications
— Developed by Curetis’ subsidiary Ares Genetics and powered by ARESdb
— Initial focus on Unyvero Pneumonia Applications
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that it will introduce its newly developed Unyvero AMR Atlas at the upcoming 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place in Amsterdam, the Netherlands, on April 13-16, 2019. Read more…
Company News: Curetis To Attend Key Conferences in the Second Quarter of 2019
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Company will be attending several key conferences in the second quarter of 2019.
Company News: ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019
– Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019.
The presentation titled “A strong HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer is associated with prolonged survival” is scheduled for Sunday, March 31, 2019, as part of the session “Predictive Biomarkers for Immunotherapy” (12:45-2:45pm, Marcus Auditorium- Bldg A-GWCC). Read more…